Menu Search
Equities

Alzamend Neuro Inc

9ZT:BER

Alzamend Neuro Inc

Actions
  • Price (EUR)0.00
  • Today's Change0.00 / --
  • Shares traded--
  • 1 Year change--
  • Beta--
Data delayed at least 15 minutes, as of Jul 16 2024 07:45 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Alzamend Neuro, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing novel products for the treatment of Alzheimer's disease (Alzheimer's), bipolar disorder (BD), major depressive disorder (MDD) and post-traumatic stress disorder (PTSD). The Company's pipeline consists of two novel therapeutic drug candidates: AL001, and ALZN002. AL001 is a patented ionic cocrystal technology delivering a therapeutic combination of lithium, salicylate and L-proline through three royalty-bearing exclusive worldwide licenses from the University of South Florida Research Foundation, Inc., (the Licensor). AL001 is used for Alzheimer's, BD, MDD and PTSD treatment. ALZN002 is a patented method using a mutant peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient’s immunological system to combat Alzheimer's by removing beta-amyloid from the brain through a royalty-bearing exclusive worldwide license from the Licensor.

  • Revenue in USD (TTM)0.00
  • Net income in USD-7.39m
  • Incorporated2016
  • Employees4.00
  • Location
    Alzamend Neuro Inc3480 Peachtree Road NE, Second Floor, Suite 103ATLANTA 30326United StatesUSA
  • Phone+1 (302) 636-5400
  • Fax+1 (302) 636-5454
  • Websitehttps://alzamend.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.